期刊文献+

皮肤脂肪及直肠黏膜活检对诊断系统性轻链淀粉样变性的意义 被引量:9

The significance of skin fat and rectal mucosal biopsy in the diagnosis of systemic light chain amyloidosis
下载PDF
导出
摘要 目的:分析我国汉族人群系统性轻链淀粉样变性(AL型淀粉样变性)的临床特征,比较不同部位活检对确诊的意义。方法:回顾性分析2009年1月至2014年10月在南京军区南京总医院肾脏科住院确诊的186例AL型淀粉样变性患者临床资料和病理诊断,以肾活检为诊断的金标准,比较皮肤脂肪活检和直肠黏膜活检对诊断AL型淀粉样变性的敏感性。结果:186例患者的平均年龄为(54.8±9.1)岁,男女比例为2.44∶1,143例(76.9%)的患者血清中检测出单克隆免疫球蛋白轻链。皮肤脂肪活检的诊断敏感性为92.5%,95%CI为88%~97%,直肠黏膜活检的诊断敏感性为94.9%,95%CI为92%~98%,结合皮肤脂肪和直肠黏膜两种活检方式,诊断阳性率达100%。结论:活检仍然是确诊AL型淀粉样变性的金标准,皮肤脂肪和直肠黏膜活检操作简单、花费低、并发症少且敏感性高,两种方法结合能够提高诊断的阳性率,对于难以进行肾活检的患者,皮肤脂肪和直肠黏膜是合适的活检取材部位。 Objective: To evaluate the skin fat biopsy and rectal mucosal biopsy in the diagnosis of AL amyloidosis. Methodology: One hundred eighty six patients diagnosed as AL amyloidosis from January 2009 to October2014 were included in this retrospective study. Using renal biopsy as the gold standard for diagnosis of AL amyloidosis,the diagnostic sensitivity between skin fat biopsy and rectal mucosal biopsy was compared. Results: There were 132 males and54 females with an average age of( 54. 8 ± 9. 1) years old. Monoclonal immunoglobulin light chain was detectable in 143patients( 76. 9%). The sensitivity of skin fat biopsy and rectal mucosal biopsy was 92. 5% [95% CI 0. 88 ~ 0. 97] and94. 9%( 95%CI 0. 92 ~ 0. 98),respectively. The positive rate of diagnosis increased to 100% by the combination of the two biopsy methods. Conclusion: Tissue biopsy continues to be the gold standard for diagnosis of AL amyloidosis. Skin fat and rectal mucosal biopsies,being simple procedures with low cost and compliment,have acceptable sensitivities. Combination of both methods can improve the positive rate. Therefore,they are preferred biopsy site for patients unsuitable of renal biopsy.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2015年第5期425-428,486,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation
基金 国家科技支撑计划课题(2013BAI09B04 2015BAI12B05) 江苏省临床医学中心项目(BL2012007)
关键词 系统性轻链淀粉样变性 皮肤脂肪活检 直肠黏膜活检 肾活检 systemic light chain amyloidosis skin fat biopsy rectal mucosal biopsy renal biopsy
  • 相关文献

参考文献19

  • 1Haider S, Ahmad N, Anaissie E, et al.Future directions in the clinical management of amyloid light-chain amyloidosis. Leuk Lymphoma, 2014,55(10) :2241-2251.
  • 2Merlini G, Bellotti V.Molecular mechanisms of amyloidosis. N Engl J Med,2003,349(6) :583-596.
  • 3黄湘华,蒋松,史明君,陈文萃,王庆文,曾彩虹,刘志红.原发性系统性淀粉样变性的预后及危险因素分析[J].肾脏病与透析肾移植杂志,2012,21(4):304-310. 被引量:19
  • 4Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol, 2014, 89 (12) : 1132-1140.
  • 5Chee CE,Lacy MQ,Dogan A,et al.Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk, 2010,10 ( 3 ) : 177-180.
  • 6van Gameren II, Hazenberg BP, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum, 2006, 54(6) :2015-2021.
  • 7Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain anayloidosis : a status report Leuk Lymphoma,2010,51(12) :2181-2187.
  • 8Gertz MA, Li CY, Shirahama T, et al. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis ( immunoglobulin light chain). Arch Intern Med, 1998,148(4) :929-933.
  • 9Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995,32( 1 ) :45-59.
  • 10Janssen S, Van Rijswijk MH, Meijer S, et al. Systemic amyloidosis : a clinical survey of 144 cases. Neth J Med, 1986,29 (11) :376-385.

二级参考文献47

  • 1刘晔,张志刚,刘学光,蒋智铭,任加强,郭慕依.慢性淋巴细胞性白血病合并膜性肾炎和肾淀粉样变一例[J].中华肾脏病杂志,2005,21(6):338-339. 被引量:4
  • 2陈惠萍.肾淀粉样变性病理诊断的体会[J].肾脏病与透析肾移植杂志,2005,14(5):433-435. 被引量:16
  • 3Li LS,Liu ZH. Epidemiologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies. Kidney Int, 2004, 66 ( 3 ) :920 - 923.
  • 4Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program,2010,2010:287 - 294.
  • 5Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995, 32 (1) :45 -59.
  • 6Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis:prognostic value and correlations with clinical features. Blood, 2010, 116 (24) :5126 -5129.
  • 7Merlini G, Bellotti V. Molecular mechanisms of amyioidosis. N Engl J Med,2003,349(6) :583 -596.
  • 8Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem, 2009,55 ( 3 ) :499 - 504.
  • 9Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol,2011,29(14) :1924- 1933.
  • 10Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol, 2009,20 ( 2 ) :444 - 451.

共引文献35

同被引文献14

引证文献9

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部